Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomised controlled trial

Ajjan, RA, Hensor, EMA, Del Galdo, F et al. (13 more authors) (2022) Oral 11β-HSD1 inhibitor AZD4017 improves wound healing and skin integrity in adults with type 2 diabetes mellitus: a pilot randomised controlled trial. European Journal of Endocrinology. ISSN 0804-4643

Metadata

Authors/Creators:
  • Ajjan, RA
  • Hensor, EMA
  • Del Galdo, F
  • Shams, K
  • Abbas, A
  • Fairclough, RJ
  • Webber, L
  • Pegg, L
  • Freeman, A
  • Taylor, AE
  • Arlt, W
  • Morgan, AW
  • Tahrani, AA
  • Stewart, PM
  • Russell, DA
  • Tiganescu, A ORCID logo https://orcid.org/0000-0003-3688-2204
Copyright, Publisher and Additional Information: © 2022 The authors 2022. This is an author produced version of an article published in European Journal of Endocrinology. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Published (online): 1 February 2022
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Cardiovascular and Metabolic Medicine (LICAMM) > Discovery & Translational Science Dept (Leeds)
Funding Information:
FunderGrant number
MRC (Medical Research Council)MC_PC_15046
Depositing User: Symplectic Publications
Date Deposited: 07 Feb 2022 11:35
Last Modified: 07 Feb 2022 11:35
Status: Published online
Publisher: BioScientifica
Identification Number: https://doi.org/10.1530/EJE-21-1197

Export

Statistics


CORE (COnnecting REpositories)